Literature DB >> 17873860

Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.

Roberto Lande1, Josh Gregorio, Valeria Facchinetti, Bithi Chatterjee, Yi-Hong Wang, Bernhard Homey, Wei Cao, Yui-Hsi Wang, Bing Su, Frank O Nestle, Tomasz Zal, Ira Mellman, Jens-Michael Schröder, Yong-Jun Liu, Michel Gilliet.   

Abstract

Plasmacytoid dendritic cells (pDCs) sense viral and microbial DNA through endosomal Toll-like receptors to produce type 1 interferons. pDCs do not normally respond to self-DNA, but this restriction seems to break down in human autoimmune disease by an as yet poorly understood mechanism. Here we identify the antimicrobial peptide LL37 (also known as CAMP) as the key factor that mediates pDC activation in psoriasis, a common autoimmune disease of the skin. LL37 converts inert self-DNA into a potent trigger of interferon production by binding the DNA to form aggregated and condensed structures that are delivered to and retained within early endocytic compartments in pDCs to trigger Toll-like receptor 9. Thus, our data uncover a fundamental role of an endogenous antimicrobial peptide in breaking innate tolerance to self-DNA and suggest that this pathway may drive autoimmunity in psoriasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873860     DOI: 10.1038/nature06116

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  632 in total

Review 1.  DNA-Based Biomaterials for Immunoengineering.

Authors:  Midori Maeda; Taisuke Kojima; Yang Song; Shuichi Takayama
Journal:  Adv Healthc Mater       Date:  2018-12-05       Impact factor: 9.933

Review 2.  Microparticles as autoadjuvants in the pathogenesis of SLE.

Authors:  David S Pisetsky; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

3.  Changes in apoptotic gene expression in lymphocytes from rheumatoid arthritis and systemic lupus erythematosus patients compared with healthy lymphocytes.

Authors:  Paul Eggleton; Lorna W Harries; Giada Alberigo; Paul Wordsworth; Nick Viner; Richard Haigh; Suzanne Donnelly; Hugh W Jones; Ian C Chikanza; Thomas W E O'Conner; Alasdair E R Thomson; Paul G Winyard
Journal:  J Clin Immunol       Date:  2010-06-09       Impact factor: 8.317

4.  Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation.

Authors:  Maria L Mouchess; Nicholas Arpaia; Gianne Souza; Roman Barbalat; Sarah E Ewald; Laura Lau; Gregory M Barton
Journal:  Immunity       Date:  2011-11-10       Impact factor: 31.745

5.  Impact of vitamin D3 on cutaneous immunity and antimicrobial peptide expression.

Authors:  Attila S Antal; Yvonne Dombrowski; Sarah Koglin; Thomas Ruzicka; Jürgen Schauber
Journal:  Dermatoendocrinol       Date:  2011-01

6.  Antimicrobial peptides inhibit polyinosinic-polycytidylic acid-induced immune responses.

Authors:  Maroof Hasan; Catarina Ruksznis; Yan Wang; Cynthia Anne Leifer
Journal:  J Immunol       Date:  2011-11-02       Impact factor: 5.422

7.  Signaling pathways mediating chemokine induction in keratinocytes by cathelicidin LL-37 and flagellin.

Authors:  Anastasia Nijnik; Jelena Pistolic; Niall C J Filewod; Robert E W Hancock
Journal:  J Innate Immun       Date:  2012-04-17       Impact factor: 7.349

8.  The human antimicrobial peptide LL-37, but not the mouse ortholog, mCRAMP, can stimulate signaling by poly(I:C) through a FPRL1-dependent pathway.

Authors:  Divyendu Singh; Rongsu Qi; Jarrat L Jordan; Lani San Mateo; C Cheng Kao
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

9.  A Bioengineered Human Skin Tissue for the Treatment of Infected Wounds.

Authors:  Christina L Thomas-Virnig; B Lynn Allen-Hoffmann
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-04       Impact factor: 4.730

Review 10.  Trafficking of endosomal Toll-like receptors.

Authors:  Bettina L Lee; Gregory M Barton
Journal:  Trends Cell Biol       Date:  2014-01-15       Impact factor: 20.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.